Corporate Profile
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder.
Investor Contact
3565 General Atomics Court, Suite 200
San Diego, CA 92121
Direct: +1.858.333.5280
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder